Clinical Trial Update: Treatment of Acromegaly With Somatostatin Analogs: GH vs. IGF-I as Primary Biochemical Target [Phase 4]

View source ↗

Summary

A completed Phase 4 trial evaluating somatostatin analog therapy for acromegaly. The study compared GH versus IGF-I as the primary biochemical target.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acromegaly

Drugs mentioned

• Octreotide (Sandostatin) (Octreotide)
• lanreotide (Somatuline) (lanreotide)

Snippet

Sponsor: University of Aarhus | Conditions: Acromegaly | Phase 4 | Status: COMPLETED